Know Cancer

forgot password

The Effects of Trans-Resveratrol (RSV) on Insulin Resistance, Inflammation, and the Metabolic Syndrome: A Placebo Controlled, Double-Blind Study.

Phase 2
30 Years
60 Years
Open (Enrolling)
Obesity, Insulin Resistance, Metabolic Syndrome

Thank you

Trial Information

The Effects of Trans-Resveratrol (RSV) on Insulin Resistance, Inflammation, and the Metabolic Syndrome: A Placebo Controlled, Double-Blind Study.

The metabolic syndrome is a serious health condition that affects about 35 percent of adults
and places them at higher risk of cardiovascular disease, diabetes, stroke and diseases
related to fatty buildups in artery walls. The underlying causes of metabolic syndrome are
obesity, being overweight, physical inactivity and genetic factors. In recent decades, the
prevalence has increased dramatically in the United States. Lifestyle interventions
including dietary modification, physical activity and weight loss form the basis of
treatment for these patients. However, research has shown that even when people are able to
incorporate these changes, they often revert back to their usual lifestyle resulting in
weight gain and continued risk for diabetes and heart disease.

Resveratrol, a natural plant derived compound found in grapes, peanuts and red wine, has
been found to reverse some of the features of the metabolic syndrome (insulin resistance,
high triglycerides, high blood pressure) in rodents. These improvements occurred without
weight loss, and were proven to be a direct result of resveratrol ingestion. Other studies
reveal improvement in cardiovascular health, tumor suppression, and longevity. However,
there are few studies investigating these beneficial effects in humans. In a systematic
review of resveratrol research, the authors conclude that "in contrast to the lacking data
of resveratrol in humans, the animal data are promising and indicate the need for further
human clinical trials." Of the small clinical studies that have been done, the results are
encouraging. Improvement in triglycerides, blood pressure and insulin resistance were noted.
Resveratrol was well tolerated without serious side effects. These studies, however, did not
recruit subjects with the metabolic syndrome, nor were they tightly controlled.

The investigators propose to prove that resveratrol, administered to subjects with the
metabolic syndrome, under controlled conditions of weight stability, common diet, and strict
compliance with the study drug, will improve the symptoms of the metabolic syndrome, thereby
decreasing the chance of developing diabetes or heart disease.

Inclusion Criteria:

- Age 30 - 60 year old men

- Willingness to be randomized to resveratrol or placebo.

- BMI 30-40

- Evidence of insulin resistance with one of the following:

2 hr oral glucose tolerance result =/>120mg/dl at 2hrs acanthosis nigricans, or HgA1C
5.7 - 7.9% AND at least 2 of the following: waist circumference > 102 cm
triglycerides > 150 but < 500 mg/dL HDL < 40 mg/dL Pre- hypertension or hypertension:
BP>120/80 mmHg but <150/90 mmHg

- Willingness to consume only study food and drink during the in-pt phases

- Willingness to avoid the use of over-the-counter medications, herbs, or supplements
within the last 30 days.

- Willingness to avoid NSAIDS (advil, aleve, motrin, etc.) and aspirin for the entire

- Willingness to avoid ingestion of any foods containing peanuts, bilberries,
blueberries, cranberries, strawberries, raspberries, grapes, grape juice, cocoa
powder, dark chocolate, and red wine throughout the entire study, including run-in

- Willingness to maintain weight for the duration of the study.

- Willingness not to start an exercise regime during study participation

Exclusion Criteria:

- Tobacco smoker any time within the last 3 months

- Bleeding disorder by history or by Bleeding Questionnaire results

- History, physical or EKG findings suggestive of CV disease including angina, MI, hx
of med/surg tx of atherosclerotic heart disease, or congestive heart disease

- BP > 145/90 after 10 minutes of rest on 2 or more screening visits

- Fasting glucose > 165 mg/dL at screening

- HbA1C > 8.0 at screening

- Current use of oral hypoglycemic agents

- Chronic glucocorticosteroid use or use of oral glucocorticosteroids for 5 days within
the last year (inhaled glucocorticosteroid use may be acceptable; this will be
determined by the PI)

- Current use of over the counter or prescription weight loss medication

- Current use or within the last 30 days, any cholesterol lowering medications
(statins, fibrates, red yeast rice, niacin).

- Hyperthyroidism or untreated hypothyroidism

- Obstructive sleep apnea, or significant symptoms suggestive of this condition.

- Current use of anticoagulants

- Known history of chronic hepatitis or liver enzymes (ALT or AST > 2.5 times the
normal upper limit)

- Known HIV infection or confirmed positive test for HIV antibodies at screening

- Inflammatory bowel disease

- Active cancer (currently under treatment)

- Other medical condition that may cause significant weight loss or gain

- Chronic or acute renal disease

- Seizure disorder

- History of any psychiatric hospital admission within the last 2 years

- History of schizophrenia, psychosis, or bipolar disease

- History, physical, social or lab findings suggestive of any medical or psychological
condition that would, in the opinion of the PI, impact the subject's ability to
successfully participate in the study.

- Alcohol or drug abuse within the last 2 years

- Any medications metabolized by cytochrome p450 3A4 (CYPA3A4) (see attachment of
these medications as an appendix)

- Any autoimmune disease (ie rheumatoid arthritis, systemic lupus erythematosis,

- Physical condition requiring special diet (ie celiac disease)

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

Reduction in Insulin resistance

Outcome Description:

Investigators anticipate resveratrol will have positive effect (ie reduction) on Insulin resistance as determined by Euglycemic hyperinsulinemic clamp

Outcome Time Frame:

4 weeks

Safety Issue:


Principal Investigator

Jeanne Walker, MSN/NP-C

Investigator Role:

Principal Investigator

Investigator Affiliation:

The Rockefeller University


United States: Institutional Review Board

Study ID:




Start Date:

October 2012

Completion Date:

November 2017

Related Keywords:

  • Obesity
  • Insulin Resistance
  • Metabolic Syndrome
  • Obesity
  • Insulin resistance
  • Metabolic syndrome
  • Pre-diabetes
  • Insulin Resistance
  • Obesity
  • Metabolic Syndrome X



The Rockefeller University New York, New York  10065